Table 3.
Number of Shared HLA-DRB1 Epitopes, by Anti-CCP Status,a DMARD Use at Baseline, and RF Status (Weighted), in a Subsample of Participants With Self-Reported Rheumatoid Arthritis at Baseline (n = 6,737b), Women's Health Initiative Rheumatoid Arthritis Study, 2009–2011
| Anti-CCP, DMARD, and RF Status | No. of Shared Epitopes |
Total | ||||||
|---|---|---|---|---|---|---|---|---|
| 0 |
1 |
2 |
||||||
| No. | Row % | No. | Row % | No. | Row % | No. | Row % | |
| Anti-CCP+ | ||||||||
| DMARD+ | 83 | 26.8 | 155 | 50.2 | 71 | 23.0 | 309 | 100.0 |
| DMARD− | 131 | 34.8 | 191 | 50.8 | 54 | 14.4 | 376 | 100.0 |
| Total | 214 | 31.2 | 346 | 50.5 | 125 | 18.3 | 685 | 100.0 |
| Anti-CCP− | ||||||||
| DMARD+/RF− | 96 | 52.7 | 74 | 40.7 | 12 | 6.6 | 182 | 100.0 |
| DMARD+/RF+ | 35 | 66.0 | 17 | 32.1 | 1 | 1.9 | 53 | 100.0 |
| DMARD−/RF− | 3,058 | 58.7 | 1,900 | 36.5 | 251 | 4.8 | 5,209 | 100.0 |
| DMARD−/RF+ | 333 | 54.8 | 261 | 42.9 | 14 | 2.3 | 608 | 100.0 |
| Total | 3,522 | 58.2 | 2,252 | 37.2 | 278 | 4.6 | 6,052 | 100.0 |
| Grand total | 3,736 | 55.4 | 2,598 | 38.6 | 403 | 6.0 | 6,737 | 100.0 |
Abbreviations: anti-CCP, anti-cyclic citrullinated peptide; DMARDs, disease-modifying antirheumatic drugs [excluding prednisone]; HLA, human leukocyte antigen; RF, rheumatoid factor.
a +, positive; –, negative.
b Excludes women who reported rheumatoid arthritis at follow-up only.